Recent Pfizer Press Releases

  • 5/29/18 8:00 am EDT

    XALKORI is the First Tyrosine Kinase Inhibitor to Receive Breakthrough Designation for the Treatment of Patients with Previously-treated Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations

    Additional Breakthrough Therapy Designation for the Treatment of Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma that is ALK-positive

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for XALKORI® (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. The FDA also granted Breakthrough Therapy designation for XALKORI for the treatment of patients with relapsed ormore...
  • 5/23/18 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that tafamidis received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients with transthyretin cardiomyopathy, a rare, fatal, and underdiagnosed condition associated with progressive heart failure.1,2 This decision is supported by topline results from the tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study, in which tafamidismore...
  • 5/22/18 1:30 pm EDT

    Study Finds Prevnar 13 was Associated With Reduced Risk of Hospitalization From Vaccine-Type Community-Acquired Pneumonia in Older Adults 1

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that results from a study analyzing real-world effectiveness data found that Prevnar 13® (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 Protein]) reduced the risk of hospitalization from vaccine-type pneumococcal community-acquired pneumonia (CAP) by 73% (95% CI: 12.8−91.5%) in adults aged 65 and older.1 Importantly, Prevnar 13 (PCV13) worked under real-world conditions where peoplemore...
  • 5/22/18 8:00 am EDT

    RSV affects 33 million children globally and leads to approximately 120,000 childhood deaths every year 1

    In the United States approximately 177,000 older adults are hospitalized annually because of RSV 2

    The clinical program aims to develop a vaccine for populations at highest risk of infection: infants through maternal immunization, and older adults through direct vaccination

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common respiratory virus that affects the lungs and airways, with significant impact on young children and older adults. The highest risk of severe outcome from RSV occurs in the first months of life.3 “A successful RSV vaccine has been an elusive goal for themore...
  • 5/17/18 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today positive top-line results of a Phase 3 study examining the use of LYRICA® (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age. Results showed that adjunctive treatment with LYRICA 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpointmore...
  • 5/16/18 5:00 pm EDT

    Data span 13 therapies across 16 types of cancer aimed at transforming patient care

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that new data from its diversified portfolio of marketed and investigational oncology medicines will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5, 2018. Data from programs in small molecules, immunotherapies, biomarker-driven medicines, as well as biosimilars, will be featured in more than 40 abstracts, including company-sponsored andmore...
  • 5/15/18 2:38 pm EDT

    RETACRIT, the First U.S. Biosimilar Erythropoiesis-Stimulating Agent (ESA), Now Approved Across All Indications

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen® and Procrit® (epoetin alfa)1, for all indications of the reference product. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent (ESA) to be approved in the U.S. “As the first approved epoetin alfa biosimilar in the U.S., RETACRIT may providemore...
  • 5/1/18 6:45 am EDT
    • First-Quarter 2018 Revenues of $12.9 Billion
    • First-Quarter 2018 Reported Diluted EPS(1) of $0.59, Adjusted Diluted EPS(2) of $0.77
    • Reaffirmed All Components of 2018 Financial Guidance
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for first-quarter 2018 and reaffirmed all components of 2018 financial guidance. Results for the first quarter of 2018 and 2017(3) are summarized below. OVERALL RESULTS   ($ in millions, except per share amountsmore...
  • 4/26/18 1:13 pm EDT

    Declares 34-Cent Second-Quarter 2018 Dividend

    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 34-cent second-quarter 2018 dividend on the company’s common stock, payable June 1, 2018, to shareholders of record at the close of business on May 11, 2018. The second-quarter 2018 cash dividend will be the 318th consecutive quarterly dividend paid by Pfizer. “In 2017, we returned nearly $12.7 billion to shareholders through dividends and share repurchases,” said Ian Read, chairmanmore...
  • 4/23/18 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that TRUMENBA® (Meningococcal Group B Vaccine) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years. This is the first Breakthrough Therapy designation for a MenB vaccine to help protect children as young as 1 year of age.more...